CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) proposed to list on the Hong

Read the full 326 word article

User Sign In